Merck (NYSE:MRK) has withdrawn its
marketing application in Europe seeking approval to use Keytruda
(pembrolizumab) to treat cancer of the esophagus. The EMA determined
that the data supporting the application were not sufficient to prove
that treatment prolonged survival.
https://seekingalpha.com/news/3536882-merck-withdraws-keytruda-application-in-europe-for-esophageal-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.